Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia: A Systematic Review and Meta-analysis

Review of 55 studies found that cholinesterase inhibitors produced small average improvements in cognition vs placebo (SMD 0.30, range 0.24 to 0.52) and no difference in function, likelihood of at least moderate improvement in clinical global impression.


Annals of Internal Medicine